{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:42:58Z","timestamp":1791434578187,"version":"4.3.3"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"FP7 - European Union","award":["261060"],"award-info":[{"award-number":["261060"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40262-017-0614-5","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T12:44:56Z","timestamp":1516711496000},"page":"1039-1053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials"],"prefix":"10.1007","volume":"57","author":[{"given":"Sven C.","family":"van Dijkman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico C. B.","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.","family":"Rauw\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1430","authenticated-orcid":false,"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"issue":"5","key":"614_CR1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1528-1157.1999.tb05562.x","volume":"40","author":"TJ Steiner","year":"1999","unstructured":"Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40(5):601\u20137.","journal-title":"Epilepsia"},{"issue":"2","key":"614_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00044011-199816020-00005","volume":"16","author":"EL Mullens","year":"1998","unstructured":"Mullens EL. Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy: a review of published randomised clinical trials. Clin Drug Investig. 1998;16(2):125\u201333.","journal-title":"Clin Drug Investig."},{"issue":"4","key":"614_CR3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","volume":"50","author":"A Fitton","year":"1995","unstructured":"Fitton A, Goa KL. Lamotrigine: An update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995;50(4):691\u2013713.","journal-title":"Drugs."},{"issue":"8948","key":"614_CR4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","volume":"345","author":"MJ Brodie","year":"1995","unstructured":"Brodie MJ, Richens A, Yuen A, UK, Lamotrigine\/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345(8948):476\u20139.","journal-title":"Lancet"},{"issue":"8","key":"614_CR5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","volume":"52","author":"D Italiano","year":"2013","unstructured":"Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52(8):627\u201345.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"614_CR6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40263-015-0268-5","volume":"29","author":"GD Anderson","year":"2015","unstructured":"Anderson GD, Saneto RP. Modified-release formulations of second-generation antiepileptic drugs: pharmacokinetic and clinical aspects. CNS Drugs. 2015;29(8):669\u201381.","journal-title":"CNS Drugs"},{"issue":"5","key":"614_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","volume":"34","author":"M Lovri\u0107","year":"2012","unstructured":"Lovri\u0107 M, Bo\u017eina N, Hajn\u0161ek S, Kuzman MR, Spori\u0161 D, Lali\u0107 Z, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit. 2012;34(5):518\u201325.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"614_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FTD.0b013e31825ee389","volume":"34","author":"CJ Landmark","year":"2012","unstructured":"Landmark CJ, Baftiu A, Tysse I, Vals\u00f8 B, Larsson PG, Rytter E, Johannessen SI. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate. Ther Drug Monit. 2012;34(4):1.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"614_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1528-1157.2000.tb00232.x","volume":"41","author":"I Ohman","year":"2000","unstructured":"Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6):709\u201313.","journal-title":"Epilepsia"},{"issue":"22","key":"614_CR10","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","volume":"70","author":"PB Pennell","year":"2008","unstructured":"Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22):2130\u20136.","journal-title":"Neurology"},{"issue":"9","key":"614_CR11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1124\/dmd.109.026609","volume":"37","author":"H Chen","year":"2009","unstructured":"Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37(9):1841\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"614_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2009.02.011","volume":"85","author":"C Fotopoulou","year":"2009","unstructured":"Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, Dudenhausen JW, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60\u20134.","journal-title":"Epilepsy Res"},{"issue":"1","key":"614_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejogrb.2013.10.021","volume":"172","author":"DAJ Pirie","year":"2014","unstructured":"Pirie DAJ, Al Wattar BH, Pirie AM, Houston V, Siddiqua A, Doug M, et al. Effects of monitoring strategies on seizures in pregnant women on lamotrigine: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;172(1):26\u201331.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"614_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","volume":"50","author":"C Chen","year":"2000","unstructured":"Chen C. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. Br J Clin Pharmacol. 2000;50(2):135\u201345.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"614_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","volume":"42","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 2000;42(1):23\u201331.","journal-title":"Epilepsy Res"},{"issue":"7","key":"614_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","volume":"63","author":"A Reimers","year":"2007","unstructured":"Reimers A, Skogvoll E, Sund JK, Spigset O. Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol. 2007;63(7):687\u201392.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"614_CR17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","volume":"33","author":"D He","year":"2012","unstructured":"He D, Wang L, Qin J, Zhang S, Lu W, Li L, et al. Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. Acta Pharmacol Sin. 2012;33(11):1417\u201323.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"614_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-013-1606-5","volume":"70","author":"B Brzakovi\u0107","year":"2014","unstructured":"Brzakovi\u0107 B, Vu\u010di\u0107evi\u0107 K, Kova\u010devi\u0107 SV, Miljkovi\u0107 B, Prostran M, Martinovi\u0107 \u017d, et al. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients\u2013nonlinear mixed effects modelling approach. Eur J Clin Pharmacol. 2014;70(2):179\u201385.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"614_CR19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1440-1681.12584","volume":"43","author":"AO Baldoni","year":"2016","unstructured":"Baldoni AO, Freitas-Lima P, de Santi Ferreira FI, Martinez EZ, Queiroz RHC, Sakamoto AC, et al. An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. Clin Exp Pharmacol Physiol. 2016;43(7):685\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"614_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-016-2190-2","volume":"73","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Ji S, Han Y, Zang L, Wang Y. Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy. Eur J Clin Pharmacol. 2017;73:445\u201353.","journal-title":"Eur J Clin Pharmacol"},{"key":"614_CR21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","volume":"25","author":"A Reimers","year":"2005","unstructured":"Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"614_CR22","first-page":"979","volume":"18","author":"R Lott","year":"2003","unstructured":"Lott R. Lamotrigine: treatment of epilepsy in the elderly. Consult Pharm. 2003;18(11):979\u201392.","journal-title":"Consult Pharm."},{"issue":"4","key":"614_CR23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","volume":"48","author":"B Punyawudho","year":"2008","unstructured":"Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, et al. Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol. 2008;48(4):455\u201363.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"614_CR24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/jcph.522","volume":"55","author":"AR Polepally","year":"2015","unstructured":"Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, et al. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: use of stable isotope methodology. J Clin Pharmacol. 2015;55(10):1101\u20138.","journal-title":"J Clin Pharmacol"},{"key":"614_CR25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.ftd.0000179843.63515.8f","volume":"27","author":"T Tomson","year":"2005","unstructured":"Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit. 2005;27:718\u201321.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"614_CR26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ane.12197","volume":"129","author":"I Wegner","year":"2014","unstructured":"Wegner I, Wilhelm AJ, Lambrechts DAJE, Sander JW, Lindhout D. Effect of oral contraceptives on lamotrigine levels depends on comedication. Acta Neurol Scand. 2014;129(6):393\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"614_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yebeh.2013.07.016","volume":"29","author":"I Wegner","year":"2013","unstructured":"Wegner I, Wilhelm AJ, Sander JW, Lindhout D. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav. 2013;29(1):217\u201321.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"614_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","volume":"69","author":"S Mallaysamy","year":"2013","unstructured":"Mallaysamy S, Johnson MG, Rao PGM, Rajakannan T, Bathala L, Arumugam K, et al. Population pharmacokinetics of lamotrigine in Indian epileptic patients. Eur J Clin Pharmacol. 2013;69(1):43\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"614_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43(5):457\u201365.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"614_CR30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","volume":"23","author":"V Chan","year":"2001","unstructured":"Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther Drug Monit. 2001;23(6):630\u20135.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"614_CR31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","volume":"69","author":"N Singkham","year":"2013","unstructured":"Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B. Influence of the UGT2B7-161C-T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol. 2013;69(6):1285\u201391.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"614_CR32","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo Y, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941\u201352.","journal-title":"J Pharm Sci"},{"issue":"10","key":"614_CR33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17425255.2016.1203900","volume":"12","author":"SC Dijkman van","year":"2016","unstructured":"van Dijkman SC, Alvarez-Jimenez R, Danhof M, Della Pasqua O. Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection \u2013 a long way to go. Expert Opinion Drug Metab Toxicol. 2016;12(10):1143\u201356.","journal-title":"Expert Opinion Drug Metab Toxicol."},{"issue":"2","key":"614_CR34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0896-6974(05)80054-4","volume":"5","author":"P Wolf","year":"1992","unstructured":"Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy. 1992;5(2):73\u20139.","journal-title":"J Epilepsy."},{"issue":"22 Pt 2","key":"614_CR35","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1212\/01.wnl.0000285493.08622.35","volume":"70","author":"JE Pi\u00f1a-Garza","year":"2008","unstructured":"Pi\u00f1a-Garza JE, Levisohn P, Gucuyener K, Mikati MA, Warnock CR, Conklin HS, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology. 2008;70(22 Pt 2):2099\u2013108.","journal-title":"Neurology"},{"issue":"14","key":"614_CR36","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.0b013e31826d5ec0","volume":"79","author":"JM Pellock","year":"2012","unstructured":"Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D\u2019Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012;79(14):1482\u20139.","journal-title":"Neurology."},{"key":"614_CR37","volume-title":"NONMEM user guide introduction to NONMEM 7.3.0","author":"RJ Bauer","year":"2014","unstructured":"Bauer RJ. NONMEM user guide introduction to NONMEM 7.3.0. Hanover: ICON Development Solutions; 2014."},{"key":"614_CR38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"614_CR39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"614_CR40","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013;2:e50.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"614_CR41","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2011","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna: The R Foundation for Statistical Computing; 2011."},{"key":"614_CR42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000360352","volume":"113","author":"M Onis de","year":"2015","unstructured":"de Onis M, The WHO. Child growth standards. World Rev Nutr Diet. 2015;113:278\u201394.","journal-title":"World Rev Nutr Diet"},{"issue":"5","key":"614_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/adc.2006.107284","volume":"92","author":"M Luscombe","year":"2007","unstructured":"Luscombe M, Owens B. Weight estimation in resuscitation: is the current formula still valid? Arch Dis Child. 2007;92(5):412\u20135.","journal-title":"Arch Dis Child"},{"issue":"7","key":"614_CR44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia"},{"issue":"11","key":"614_CR45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","volume":"71","author":"L Liu","year":"2015","unstructured":"Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y. Influence of valproic acid concentration and polymorphism of UGT1A4\u22173, UGT2B7 -161C\u00a0>\u00a0T and UGT2B7\u22172 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol. 2015;71(11):1341\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"614_CR46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","volume":"82","author":"D Milosheska","year":"2016","unstructured":"Milosheska D, Lorber B, Vovk T, Kastelic M, Dol\u017ean V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016;82:399\u2013411.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"614_CR47","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","volume":"30","author":"N Rivas","year":"2008","unstructured":"Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dom\u00ednguez-Gil A, et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit. 2008;30(4):483\u20139.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"614_CR48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00228-006-0144-9","volume":"62","author":"AM Almeida","year":"2006","unstructured":"Almeida AM, Falc\u00e3o AC, Sales F, Baldeiras I, Rocha MJ, Caramona MM. Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. Eur J Clin Pharmacol. 2006;62(9):737\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"614_CR49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1528-1157.2003.46902.x","volume":"44","author":"DV Lardizabal","year":"2003","unstructured":"Lardizabal DV, Morris HH, Hovinga CA, Mar Del Carre\u00f1o M. Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. Epilepsia. 2003;44(4):536\u20139.","journal-title":"Epilepsia"},{"issue":"4","key":"614_CR50","first-page":"373","volume":"39","author":"TH Grasela","year":"1999","unstructured":"Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. Pharmacokinet Pharmacodyn. 1999;39(4):373\u201384.","journal-title":"Pharmacokinet Pharmacodyn."},{"key":"614_CR51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(91)90012-5","volume":"10","author":"RE Ramsay","year":"1991","unstructured":"Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res. 1991;10:191\u2013200.","journal-title":"Epilepsy Res"},{"issue":"1","key":"614_CR52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25\u201336.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"614_CR53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2012.04206.x","volume":"74","author":"M Cella","year":"2012","unstructured":"Cella M, Knibbe C, de Wildt SN, Van Gerven J, Danhof M, Della Pasqua O. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol. 2012;74(3):525\u201335.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"614_CR54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bcp.12322","volume":"78","author":"C Piana","year":"2014","unstructured":"Piana C, Danhof M, Della Pasqua O. Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research. Br J Clin Pharmacol. 2014;78(1):145\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"614_CR55","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","volume":"62","author":"D Weintraub","year":"2005","unstructured":"Weintraub D, Buchsbaum R, Resor S, Hirsch L. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62(9):1432\u20136.","journal-title":"Arch Neurol"},{"issue":"10","key":"614_CR56","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1528-1167.2011.03217.x","volume":"52","author":"H Arif","year":"2011","unstructured":"Arif H, Svoronos A, Resor SR Jr, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia. 2011;52(10):1905\u201313.","journal-title":"Epilepsia"},{"issue":"438","key":"614_CR57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cca.2014.09.004","volume":"2014","author":"H-J Kim","year":"2015","unstructured":"Kim H-J, Kim T-E, Joo EY, Seo D-W, Lee S-Y, Hong SB. Effect of comedication on lamotrigine clearance in Korean epilepsy patients. Clin Chim Acta. 2015;2014(438):269\u201373.","journal-title":"Clin Chim Acta"},{"key":"614_CR58","unstructured":"Lamotrigine (Rx). Lamictal, Lamictal XR, Lamictal ODT: Dosing and uses. http:\/\/reference.medscape.com\/drug\/lamictal-lamotrigine-343012. Accessed 25 Sept 2017."},{"issue":"9","key":"614_CR59","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.107.015214","volume":"35","author":"SJ Miyagi","year":"2007","unstructured":"Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos. 2007;35(9):1587\u201392.","journal-title":"Drug Metab Dispos"},{"key":"614_CR60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","volume":"50","author":"CP Strassburg","year":"2002","unstructured":"Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50:259\u201365.","journal-title":"Gut"},{"issue":"10","key":"614_CR61","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1038\/psp.2012.12","volume":"1","author":"EHJ Krekels","year":"2012","unstructured":"Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: part II\u2014sensitivity to physiological and physicochemical properties. CPT Pharmacomet Syst Pharmacol. 2012;1(10):e10.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"614_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13400","author":"SC Dijkman van","year":"2017","unstructured":"van Dijkman SC, Rauw\u00e9 WM, Danhof M, Della Pasqua O. Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children. Br J Clin Pharmacol. 2017;. https:\/\/doi.org\/10.1111\/bcp.13400 (Epub 16 Aug 2017).","journal-title":"Br J Clin Pharmacol"},{"key":"614_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.777","author":"SC Dijkman van","year":"2017","unstructured":"van Dijkman SC, Wicha SG, Danhof M, Della Pasqua OE. Individualized dosing algorithms and therapeutic monitoring for antiepileptic drugs. Clin Pharmacol Ther. 2017;. https:\/\/doi.org\/10.1002\/cpt.777 (Epub 27 Jun 2017).","journal-title":"Clin Pharmacol Ther"}],"updated-by":[{"DOI":"10.1007\/s40262-018-0660-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0614-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0614-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0614-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T01:25:10Z","timestamp":1660353910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0614-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0614-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40262-018-0660-7","asserted-by":"object"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,23]]}}}